KRAS and colorectal carcinoma: Large scale data sharing and transcriptomics analyses by an international consortium have led to the identification of four consensus molecular subtypes (CMSs) of CRC: CMS1 (hypermutated, MSI, BRAF mutation, CIMP high, immune activation), CMS2 (epithelial, marked WNT and MYC signalling activation), CMS3 (epithelial and evident metabolic dysregulation, KRAS mutation) and CMS4 (mesenchymal, prominent transforming growth factor-β (TGF-β) activation, stromal invasion and angiogenesis) [18].